Bill Text: NY A03741 | 2019-2020 | General Assembly | Introduced

---

Bill Title: Requires practitioners who administer naloxone or another overdose reversal agent to a patient in the case of a suspected or confirmed overdose to report the administration of the agent to the prescription monitoring program registry.

Spectrum: Bipartisan Bill

Status: (Introduced - Dead) 2020-01-08 - referred to health [A03741 Detail]

Download: New_York-2019-A03741-Introduced.html

---

                STATE OF NEW YORK
        ________________________________________________________________________
                                          3741
                               2019-2020 Regular Sessions
                   IN ASSEMBLY
                                    January 31, 2019
                                       ___________
        Introduced by M. of A. McDONALD, MOSLEY, GALEF, JOYNER, MONTESANO, MORI-
          NELLO,  CAHILL,  GOTTFRIED, RAIA, WOERNER, LAWRENCE, BLAKE, B. MILLER,
          STECK, OTIS, COLTON, ASHBY -- Multi-Sponsored by -- M. of A.  BLANKEN-
          BUSH,  BRAUNSTEIN,  CROUCH, GIGLIO, McDONOUGH, SIMON, THIELE, WALSH --
          read once and referred to the Committee on Health
        AN ACT to amend the public health law, in relation to requiring  practi-
          tioners  who administer naloxone or another overdose reversal agent to
          a patient in the case of a suspected or confirmed overdose  to  report
          the administration of the agent to the prescription monitoring program
          registry
          The  People of the State of New York, represented in Senate and Assem-
        bly, do enact as follows:
     1    Section 1. Subdivision 9 of section 3343-a of the public health law is
     2  renumbered subdivision 10 and a new subdivision 9 is added  to  read  as
     3  follows:
     4    9.  Administration  of  overdose reversal agents. (a) Any practitioner
     5  who administers naloxone or another overdose reversal agent to a patient
     6  in the case of a suspected or confirmed overdose shall report the admin-
     7  istration of the agent to the prescription monitoring  program  registry
     8  within  seventy-two  hours  of administration. Such report shall contain
     9  the following information if available: (i) the  name  of  the  patient;
    10  (ii) the address of the patient; (iii) the date of birth of the patient;
    11  (iv)  the time and place of the administration of the agent; and (v) the
    12  identity of the person who administered the naloxone to the patient.
    13    (b) Any report made pursuant to the terms of this subdivision shall be
    14  considered to be made by the reporter in the course of his or her duties
    15  and shall be directly related to patient care.
    16    § 2. This act shall take effect January 1, 2021.
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD00587-01-9